The U.S. Centers for Medicare & Medicaid Services has granted advanced diagnostic laboratory test (ADLT) status to Castle Biosciences' TissueCypher Barrett's esophagus test.
The test aims to predict whether patients with Barrett's esophagus will develop esophageal cancer or high-grade dysplasia. The status was effective March 24.
Achieving ADLT status confirms TissueCypher meets the highly selective criteria established under the Protecting Access to Medicare Act of 2014, according to Castle.
